The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
Open accessAbstract
The majority of heterocycle compounds and typically common heterocycle fragments present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility and unique physicochemical properties, have poised them as true cornerstones of medicinal chemistry. Apart from the already marketed drugs, there are many other being investigated for their promising activity against several malignancies. In particular, anticancer research has been capitalizing on the intrinsic versatility and dynamic core scaffold of these compounds. Nevertheless, as for any other promising anticancer drugs, heterocyclic compounds do not come without shortcomings. In this review, we provide for a concise overview of heterocyclic active compounds and families and their main applications in medicine. We shall focus on those suitable for cancer therapy while simultaneously addressing main biochemical modes of action, biological targets, structure-activity relationships as well as intrinsic limitation issues in the use of these compounds. Finally, considering the advent of nanotechnology for effective selective targeting of drugs, we shall discuss fundamental aspects and considerations on nanovectorization of such compounds that may improve pharmacokinetic/pharmacodynamic properties of heterocycles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Determining the Size and Shape Dependence of Gold Nanoparticle Uptake into Mammalian Cells
Chithrani, B. D., Ghazani, A. A., & Chan, W. C. W. (2006) · Nano Letters · doi:10.1021/nl052396o · Cited by 4,879
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 8×
“Since its discovery, the synthesis method has seen much improvement, allowing a more large scale production and smaller sizes, from 20–50 nm. Liposomal doxorubicin (Doxil®) was the first nanodevice approved by FDA for cancer treatment [79,80], and an additional five formulations have already attained approval—DaunoXom…”
BackgroundInfluentialNanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Shukla, R., Bansal, V., Chaudhary, M., Basu, A., Bhonde, R. R., & Sastry, M. (2005) · Langmuir · doi:10.1021/la0513712 · Cited by 1,687
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Toxicity and cellular uptake of gold nanoparticles: what we have learned so far?
Alkilany, A. M., & Murphy, C. J. (2010) · Journal of Nanoparticle Research · doi:10.1007/s11051-010-9911-8 · Cited by 1,485
Yin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452
Dendrimers and dendritic polymers in drug delivery
Gillies, E. R., & Fréchet, J. M. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03276-3 · Cited by 1,367
Iversen, T.-G., Skotland, T., & Sandvig, K. (2011) · Nano Today · doi:10.1016/j.nantod.2011.02.003 · Cited by 1,239
Endocytosis and exocytosis of nanoparticles in mammalian cells
Park, J. H., & Oh, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s26592 · Cited by 1,176
Cellular Uptake, Intracellular Trafficking, and Cytotoxicity of Nanomaterials
Zhao, F., Zhao, Y., Liu, Y., Chang, X., Chen, C., & Zhao, Y. (2011) · Small · doi:10.1002/smll.201100001 · Cited by 1,175
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy
Doane, T. L., & Burda, C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15260f · Cited by 1,098
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Site-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Uptake and Intracellular Fate of Surface-Modified Gold Nanoparticles
Nativo, P., Prior, I. A., & Brust, M. (2008) · ACS Nano · doi:10.1021/nn800330a · Cited by 659
Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647
Heterocycles in drugs and drug discovery
Gomtsyan, A. R. (2012) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-012-0960-z · Cited by 615
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Szebeni, J. (2005) · Toxicology · doi:10.1016/j.tox.2005.07.023 · Cited by 611
Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy
Parhi, P., Mohanty, C., & Sahoo, S. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.010 · Cited by 573
Shaping Cancer Nanomedicine: The Effect of Particle Shape on The In Vivo Journey of Nanoparticles
Toy, R., Peiris, P. M., Ghaghada, K. B., & Karathanasis, E. (2014) · Nanomedicine · doi:10.2217/nnm.13.191 · Cited by 570
Bioactive Benzofuran derivatives: A review
Khanam, H., & Shamsuzzaman (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.039 · Cited by 554
Noble Metal Nanoparticles Applications in Cancer
Conde, J., Doria, G., & Baptista, P. (2012) · Journal of Drug Delivery · doi:10.1155/2012/751075 · Cited by 541
Self-citationTargeted therapy using nanotechnology: focus on cancer
Sechi, M., Sanna, V., & Pala, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s36654 · Cited by 493
Bell, F. W., Cantrell, A. S., Hoegberg, M., Jaskunas, S. R., Johansson, N. G., Jordan, C. L., Kinnick, M. D., Lind, P., & Morin, J. M. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00025a010 · Cited by 456
Development of in vitro systems for nanotoxicology: methodological considerations
Stone, V., Johnston, H., & Schins, R. P. F. (2009) · Critical Reviews in Toxicology · doi:10.1080/10408440903120975 · Cited by 427
Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery
Kesharwani, P., & Iyer, A. K. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.012 · Cited by 380
Markman, M., & Mekhail, T. M. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.6.755 · Cited by 375
Size-dependent toxicity and cell interaction mechanisms of gold nanoparticles on mouse fibroblasts
Coradeghini, R., Gioria, S., García, C. P., Nativo, P., Franchini, F., Gilliland, D., Ponti, J., & Rossi, F. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2012.11.022 · Cited by 359
Indole, a core nucleus for potent inhibitors of tubulin polymerization
Brancale, A., & Silvestri, R. (2007) · Medicinal Research Reviews · doi:10.1002/med.20080 · Cited by 344
Feldman, E. J., Lancet, J. E., Kolitz, J. E., Ritchie, E. K., Roboz, G. J., List, A. F., Allen, S. L., Asatiani, E., Mayer, L. D., Swenson, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5961 · Cited by 310
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin, S., Nehoff, H., & Greish, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.013 · Cited by 309
Nanotechnological carriers for cancer chemotherapy: The state of the art
Estanqueiro, M., Amaral, M. H., Conceição, J., & Sousa Lobo, J. M. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.12.041 · Cited by 298
Physico-chemical features of engineered nanoparticles relevant to their toxicity
Fubini, B., Ghiazza, M., & Fenoglio, I. (2010) · Nanotoxicology · doi:10.3109/17435390.2010.509519 · Cited by 297
Pharmacological Significance of Synthetic Heterocycles Scaffold: A Review
Dua, R., & Shrivastava, S. (2011) · Cited by 264
Antibody‐Drug Conjugates for the Treatment of Cancer
Flygare, J. A., Pillow, T. H., & Aristoff, P. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12085 · Cited by 232
Design of Multifunctional Gold Nanoparticles for In Vitro and In Vivo Gene Silencing
Conde, J., Ambrosone, A., Sanz, V., Hernandez, Y., Marchesano, V., Tian, F., Child, H., Berry, C. C., Ibarra, M. R., Baptista, P. V., et al. (2012) · ACS Nano · doi:10.1021/nn3030223 · Cited by 232
Self-citationNanomaterials in combating cancer: Therapeutic applications and developments
Nazir, S., Hussain, T., Ayub, A., Rashid, U., & MacRobert, A. J. (2014) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2013.07.001 · Cited by 230
Vrignaud, P., Sémiond, D., Lejeune, P., Bouchard, H., Calvet, L., Combeau, C., Riou, J.-F., Commerçon, A., Lavelle, F., & Bissery, M.-C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3146 · Cited by 229
Zolot, R. S., Basu, S., & Million, R. P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3980 · Cited by 227
Intracellular uptake, transport, and processing of gold nanostructures
Chithrani, D. B. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.507787 · Cited by 213
Engineered nanomaterial uptake and tissue distribution: from cell to organism
Huwyler, J., Kettiger, H., Schipanski, A., & Wick, P. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s49770 · Cited by 210
Antibody–drug conjugates: Basic concepts, examples and future perspectives
Casi, G., & Neri, D. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.026 · Cited by 210
Nanotechnology platforms and physiological challenges for cancer therapeutics
Kim, K. Y. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2006.12.002 · Cited by 201
Coumarin-based drugs: a patent review (2008 – present)
Kontogiorgis, C., Detsi, A., & Hadjipavlou-Litina, D. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.678835 · Cited by 187
Thiosulfoxide (sulfane) sulfur: new chemistry and new regulatory roles in biology
Toohey, J., & Cooper, A. (2014) · Molecules · doi:10.3390/molecules190812789 · Cited by 173
Liu, N., Li, X., Huang, H., Zhao, C., Liao, S., Yang, C., Liu, S., Song, W., Lu, X., Lan, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2113 · Cited by 173
Cao, X., Sun, Z., Cao, Y., Wang, R., Cai, T., Chu, W., Hu, W., & Yang, Y. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4016284 · Cited by 161
Sherer, C., & Snape, T. J. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.007 · Cited by 160
Is Anticancer Drug Development Heading in the Right Direction?
Hambley, T. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3786 · Cited by 153
FDA's Approach to Regulation of Products of Nanotechnology
Hamburg, M. A. (2012) · Science · doi:10.1126/science.1205441 · Cited by 152
Dinutuximab: First Global Approval
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0399-5 · Cited by 147
Sarris, A. H., Hagemeister, F. B., Romaguera, J. E., Rodríguez, M., McLaughlin, P. J., Tsimberidou, A. M., Medeiros, L. J., Samuels, B. I., Pate, O., Oholendt, M. S., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008348010437 · Cited by 143
Benzimidazole clubbed with triazolo-thiadiazoles and triazolo-thiadiazines: New anticancer agents
Husain, A., Rashid, M., Yar, M. S., Siddiqui, A. A., & Mishra, R. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.011 · Cited by 139
1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells
Valente, S., Trisciuoglio, D., Luca, T. D., Nebbioso, A., Labella, D., Lenoci, A., Bigogno, C., Dondio, G. M., Miceli, M., Brosch, G., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500303u · Cited by 138
Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer
Tejada‐Berges, T., Granai, C. O., Gordinier, M. E., & Gajewski, W. H. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.2.143 · Cited by 125
Patlolla, A. K., Knighten, B., & Tchounwou, P. B. (2010) · PubMed · Cited by 122
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
Traina, T. A., Cadoo, K. A., & Gucalp, A. (2014) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s46725 · Cited by 113
Husain, A., Rashid, M., Mishra, R., Parveen, S., Shin, D., & Kumar, D. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.07.038 · Cited by 107
PARK, S.-H. G., LEE, J. G., Berek, J. S., & HU, M. Y. C.-T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2579 · Cited by 106
Fiorcari, S., Brown, W. S., McIntyre, B. W., Estrov, Z. E., Maffei, R., O'Brien, S. M., Sivina, M., Hoellenriegel, J., Wierda, W. G., Keating, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083830 · Cited by 98
Conde, J., Larguinho, M., Gaspar‐Cordeiro, A., Raposo, L. R., Costa, P. M., Santos, S., Diniz, M., Fernandes, A. R., & Baptista, P. V. (2013) · Nanotoxicology · doi:10.3109/17435390.2013.802821 · Cited by 98
Self-citationPeralta, D. V., Heidari, Z., Dash, S., & Tarr, M. A. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b00858 · Cited by 98
Gold nanoparticle-based theranostics: disease diagnostics and treatment using a single nanomaterial
Baptista, P. V., Fernandes, A. R., Figueiredo, S., Vinhas, R., Cordeiro, M., Carlos, F. F., & Mendo, A. S. (2015) · Nanobiosensors in Disease Diagnosis · doi:10.2147/ndd.s60285 · Cited by 96
Self-citationNanotechnology-Based Precision Tools for the Detection and Treatment of Cancer
Stegh, A. H., Petrosko, S. H., Meade, T. J., & Mirkin, C. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-16555-4 · Cited by 93
Azab, M. E., Youssef, M. M., & El‐Bordany, E. A. A. (2013) · Molecules · doi:10.3390/molecules18010832 · Cited by 86
Awada, A. H., García, A. A., Chan, S. Y. T., Jérusalem, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70429-7 · Cited by 80
Just so stories: The random acts of anti-cancer nanomedicine performance
Moghimi, S. M., & Farhangrazi, Z. S. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.04.011 · Cited by 75
Drug delivery: Beyond active tumour targeting
Sagnella, S. M., McCarroll, J. A., & Kavallaris, M. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.04.012 · Cited by 74
Mefloquine–Oxazolidine Derivatives: A New Class of Anticancer Agents
Rodrigues, F. A. R., Bomfim, I. D. S., Cavalcanti, B. C., Pessoa, C., Gonçalves, R. S. B., Wardell, J. L., Wardell, S. M. S. V., & Souza, M. V. N. D. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12210 · Cited by 63
Choi, M.-H., Jo, H., Park, H.-J., Kumar, A. S., Lee, J., Yun, J., Kim, Y., Han, S., Jung, J., Cho, J., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.050 · Cited by 59
Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine
Martins, P. H. D. F., Rosa, D., Fernandes, A. R., & Baptista, P. V. (2014) · Current Nanomedicine · doi:10.2174/1877912304666140304000133 · Cited by 52
Self-citationCABRAL, R. M., & Baptista, P. V. (2013) · Nano LIFE · doi:10.1142/s179398441330001x · Cited by 50
Self-citationOrnes, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314120110 · Cited by 50
1,2,4-Oxadiazoles: A new class of anti-prostate cancer agents
Khatik, G. L., Kaur, J., Kumar, V., Tikoo, K., & Nair, V. A. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.059 · Cited by 38
Devriese, L. A., Mergui‐Roelvink, M., Wanders, J., Jenner, A., Edwards, G., Reyderman, L., Copalu, W., Peng, F.-L., Marchetti, S., Beijnen, J. H., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9829-3 · Cited by 34
Murugan, M., Anthony, K. J. P., Jeyaraj, M., Krishnaraj, R., & Gurunathan, S. (2013) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2013.08.021 · Cited by 32
Teicher, B. A. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000108 · Cited by 32
Huang, S., Hsu, P., Chen, M., Li, W., More, S. V., Lu, K., & Wang, Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.26401 · Cited by 31
Molecular modelling and drug design
Meyer, E. F., Swanson, S. M., & Williams, J. A. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00069-8 · Cited by 29
In silico pharmacology: drug design and discovery’s gate to the future
Noori, H. R., & Spanagel, R. (2013) · In Silico Pharmacology · doi:10.1186/2193-9616-1-1 · Cited by 29
Nanomedicine: The Promise and Challenges in Cancer Chemotherapy
Naguib, Y. W., & Cui, Z. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-8739-0_11 · Cited by 28
Synthesis and evaluation of flavanones as anticancer agents.
Murti, Y., & Mishra, P. (2014) · PubMed · Cited by 22
Chen, X., Zhou, H. J., Huang, Q., Lu, L., & Wang, M. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520614666140610102651 · Cited by 21
Hou, J. L., Zhao, W., Huang, Z., Yang, S., Wang, L., Yu, J., Zhou, Z., Zheng, M., Jiang, J., Li, S., et al. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12484 · Cited by 18
Lee, J. E., Perkins, J., Barnett, M. E., Sarpong, D. F., & Sung, J. (2010) · PubMed · Cited by 17
Nanotechnology for Cancer Diagnostics and Therapy – An Update on Novel Molecular Players
Fernandes, A. R., & Baptista, P. V. (2014) · Current Cancer Therapy Reviews · doi:10.2174/157339470903140220144703 · Cited by 8
Self-citationThe emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia
Molica, S. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2013.831324 · Cited by 2
Cited by
A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications
Kerru, N., Gummidi, L., Maddila, S., Gangu, K. K., & Jonnalagadda, S. B. (2020) · Molecules · doi:10.3390/molecules25081909 · Cited by 1,716
Prescribed drugs containing nitrogen heterocycles: an overview
Heravi, M. M., & Zadsirjan, V. (2020) · RSC Advances · doi:10.1039/d0ra09198g · Cited by 1,194
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
Kumar, A., Singh, A. K., Singh, H., Vijayan, V., Kumar, D., Naik, J., Thareja, S., Yadav, J. P., Pathak, P., Grishina, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020299 · Cited by 363
Natural source, bioactivity and synthesis of benzofuran derivatives
Miao, Y.-H., Hu, Y.-H., Yang, J., Liu, T., Sun, J., & Wang, X.-J. (2019) · RSC Advances · doi:10.1039/c9ra04917g · Cited by 354
Recent advances in chemistry and therapeutic potential of functionalized quinoline motifs – a review
Ajani, O. O., Iyaye, K. T., & Ademosun, O. T. (2022) · RSC Advances · doi:10.1039/d2ra02896d · Cited by 305
Metadata
- Authors
- Martins, P., Jesus, J., Santos, S., Raposo, L., Roma-Rodrigues, C., Baptista, P., & Fernandes, A.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-09-16
- Volume
- 20
- Issue
- 9
- Pages
- 16852-16891
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W1709997767
- Cited by
- 716
- References
- 98
- FWCI
- 14.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.